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Background: Primary myelofibrosis is a myeloproliferative disorder characterized by bone marrow fibrosis,
abnormal cytokine expression, splenomegaly and anemia. The activation of JAK2 and the increased levels of
circulating proinflammatory cytokines seem to play an important role in the pathogenesis of myelofibrosis. Novel
therapeutic agents targeting JAKs have been developed for the treatment of myeloproliferative disorders.
Ruxolitinib (INCB018424) is the most recent among them.
Case presentation: To our knowledge, there is no evidence from clinical trials of an increased risk of tuberculosis
during treatment with JAK inhibitors. Here we describe the first case of tuberculosis in a patient treated with
Ruxolitinib, a male with a 12-year history of chronic idiopathic myelofibrosis admitted to our Institute because of
fever, night sweats, weight loss and an enlarging mass in the left inguinal area for two months.
Conclusion: Treatment with Ruxolitinib may have triggered the reactivation of latent tuberculosis because of an
inhibition of Th1 response. Our case highlights the importance of an accurate screening for latent tuberculosis
before starting an anti-JAK 2 treatment.
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Primary myelofibrosis is a myeloproliferative disorder
characterized by bone marrow fibrosis, abnormal cyto-
kine expression, splenomegaly and anemia. The molecu-
lar mechanisms underlying pathogenesis are poorly
understood. Recent studies have implicated mutations
that directly or indirectly lead to a deregulated activation
of tyrosine-protein kinases, Janus-activated kinase 2
(JAK2) [1,2]. Therefore, the activation of JAK2 and the
increased levels of circulating proinflammatory cytokines
seem to play an important role in the pathogenesis of
myelofibrosis [3]. Novel therapeutic agents targeting
JAKs have been developed for the treatment of myelo-
proliferative disorders. Ruxolitinib (INCB018424) is the
most recent among them [4,5]. The suggested mechan-
ism of action of Ruxolitinib is the attenuation of cyto-
kine signaling via the inhibition of JAK1 and JAK2,
resulting in antiproliferative and proapoptotic effects.* Correspondence: claudia.colomba@libero.it
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ductions in splenomegaly and constitutional symptoms [6].
To our knowledge, there is no evidence from clinical
trials of an increased risk of tuberculosis during treat-
ment with JAK inhibitors [6]. Here we describe the first
case of tuberculosis in a patient treated with Ruxolitinib.
Case presentation
A male with a 12-year history of chronic idiopathic mye-
lofibrosis was admitted to the Institute of Infectious Dis-
eases, “Paolo Giaccone” University Polyclinic in Palermo,
because of fever, night sweats, weight loss and an enlar-
ging mass in the left inguinal area for two months. Our
patient had been enrolled in the COMFORT-II study, a
randomized, open-label Phase III study of oral JAK2 in-
hibitor Ruxolitinib versus best available therapy in
patients with primary myelofibrosis, post-polycythemia
vera myelofibrosis, and post-essential thrombocythemia
myelofibrosis. On admission, physical examination showed
a lymph node enlargment in the left inguinal area, cre-
pitations at right lung base and diminished vesicular mur-
murs at left lung base on pulmonary auscultation, firmal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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slow speech without signs of meningeal irritation. La-
boratory test results revealed RBC 2770000 cells/mm3,
Hb 8.1 g/dL, WBC 5490 cells/mm3 (N 64.8% L 26% M
8.4%), PLT 69000 cells/mm3, total and direct bilirubin
3.56/2.49 mg/dL respectively, albumin 2.7 g/dL, erythro-
cyte sedimentation rate (ESR) 15 mm, C-reactive protein
(CRP) 6.94 mg/dL. The patient underwent inguinal lym-
phadenectomy and microbiological examination showed
acid-alcohol resistant bacilli and positive polymerase
chain reaction (PCR) for Mycobacterium tuberculosis.
The chest radiograph revealed consolidation in the left
middle lung field. A QuantiFERON-TB gold was per-
formed with positive result (11.3 U/mL). M. tuberculosis
was cultured from three sputum samples. Abdominal
CT-scan showed confluent and colliquative para-aortic,
inter aorta-cava, iliac and left inguinal lymph nodes. The
standard tuberculosis treatment with isoniazid, rifampi-
cin, pyrazinamide and ethambutol was started.
Discussion
The main side effect of inhibitors of JAK1 and 2 can be
an increased risk of infections, related to a depressed
Th1 response and a reduced production of gamma inter-
feron (INF-γ) [7].
IFN-γ is a key cytokine involved in protective immun-
ity against Mycobacterium tuberculosis, regulating the
expression of genes involved in antimycobacterial ef-
fector functions.
Mycobacterium tuberculosis leads to the activation of
alveolar macrophages, with production of cytokines that
limit the growth of ingested organisms. Alveolar macro-
phages and dendritic cells produce IL-12 and additional
cyto- and chemokines such as TNF-α, IL-1, IL-6, IL-15,
IL-18. IL-12 plays as a master regulator of Th1 response
inducing the production of IFN-γ. IL-12 binds to a high
affinity receptor (IL-12R) and activates Janus family tyro-
sine kinases, leading to phosphorylation of tyrosine res-
idues of STAT3 and STAT4. The final event is the
transcription of IFN-γ mRNA. IFN-γ activated macro-
phages produce bactericidal superoxide and reactive ni-
trogen intermediates, as well as IL-12, IL-1 and IL-6 [8].
Conclusion
Treatment with Ruxolitinib may have triggered the re-
activation of latent tuberculosis because of an inhibition
of Th1 response. Our case highlights the importance of
an accurate screening for latent tuberculosis before start-
ing an anti-JAK 2 treatment.
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